Aktienanalyse zu OmniAb Inc (OABI)OABIOmniAb Inc

OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

OmniAb Inc (OABI) appears to be a good buy right now due to its current price of $4.59, which is significantly lower than the analyst price target of $6, indicating a potential upside of 30.3%. Additionally, the company has shown strong revenue growth, with Q2 2026 revenue at $13.4 million, a 244% increase from the same quarter last year. However, the main risk is the negative earnings per share (EPS) estimate of -0.12 for the next earnings report on October 30, 2026, which could affect investor sentiment.